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Patients
Alexey A. Larionov*
Department of Medical Genetics, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom
The median survival of patients with human epidermal growth factor receptor 2 (HER2)-
positive metastatic breast cancer (MBC) has more than doubled, since the discovery 
of HER2-targeted treatments: it rose from less than 2 years in 2001 (prior introduction 
of trastuzumab) to more than 4 years in 2017. The initial generation of HER2-targeted 
therapies included trastuzumab with taxanes in the first line, followed by the addition 
of lapatinib and by a switch to another cytotoxic agent after progression. Results of 
CLEOPATRA, EMILIA, and TH3RESA trials have changed this clinical practice. The 
current consensus includes horizontal dual blockade (trastuzumab + pertuzumab) with 
taxanes or vinorelbine in the first line, followed by trastuzumab-emtansine (T-DM1) in 
the second line, with addition of lapatinib in the later lines of treatment. However, the 
fast and simultaneous development of new drugs led to a relative shortage of clinical 
evidence to support this sequence. Triple-positive breast cancers (TPBC), which express 
both hormonal receptors and HER2, constitute nearly half of HER2-positive cases. For 
these tumors, the current consensus is to add endocrine therapy after completion of 
cytotoxic treatment. Again, this consensus is not fully evidence-based. In view of the 
recent progress in treatment of estrogen-receptor positive breast cancers, a series of 
trials is evaluating addition of CDK4/6 inhibitors, aromatase inhibitors or fulvestrant to 
HER2-targeted and cytotoxic chemotherapy in TPBC patients. Despite the remarkable 
progress in treatment of HER2-positive breast cancer, metastatic disease is still incurable 
in the majority of patients. A wide range of novel therapies are under development to pre-
vent and overcome resistance to current HER2-targeted agents. This review discusses 
pivotal clinical trials that have shaped current clinical practices, the current consensus 
recommendations, and the new experimental treatments in metastatic HER2-positive 
breast cancer.
Keywords: HeR2, metastatic breast cancer, trastuzumab, pertuzumab, lapatinib, trastuzumab-emtansine, triple-
positive breast cancer, therapies
Abbreviations: HER2 (1,3,4), human epidermal growth factor receptor 2 (1,3,4); EGFR, human epidermal growth factor recep-
tor (same as HER1); ERBB, human epidermal growth factor receptors family (same as HER family; historically named after 
erbB gene of avian erythroblastosis virus); BC, breast cancer; MBC, metastatic breast cancer; EBC, early breast cancer; TPBC, 
triple positive breast cancer; PFS, median progression-free survival; OS, median overall survival; ORR, objective response rate; 
BM, brain metastases; BBB, blood brain barrier; AI, aromatase inhibitor; ER, estrogen receptor; NK, natural killer cells; ADC, 
antibody-drug conjugate; TKI, tyrosine kinase inhibitor.
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iNTRODUCTiON
Human epidermal growth factor receptor 2 (HER2) was discov-
ered as a human proto-oncogene in 1985 through its homology 
with an avian viral oncogene v-erbB and with the human EGFR 
(human epidermal growth factor receptor) gene. In 1987, D. 
Slamon with co-authors described amplification of HER2 in 
~30% of clinical samples of breast cancers along with its associa-
tion with aggressive disease and poor survival (1). Trastuzumab, 
the first HER2-targeted drug, was successfully tested in 2001 (2). 
Trastuzumab’s success triggered development of other HER2-
targeted agents, including new antibodies (pertuzumab), kinase-
inhibitors (lapatinib, neratinib), and antibody-conjugated drugs 
(trastuzumab-emtanasine). Numerous trials were conducted to 
select optimal combinations of HER2-targeting agents with cyto-
toxic therapies. As a result, HER2-positive breast cancer patients 
now have one of the best survival rates if targeted treatments are 
applied (3–6).
Human epidermal growth factor receptor 2 is a member of 
human epidermal growth factor receptors (ERBB) family of 
membrane tyrosine-kinase receptors, which also include EGFR, 
HER3, and HER4 (Figure 1A). The generic structure of an ERBB 
receptor includes extra-cellular ligand-binding domains and 
an intra-cellular kinase domain. ERBB receptors are activated 
by a number of peptide ligands, including EGF, TGF-alpha, 
amphiregulin (for EGFR), and neuregulins (for HER3 and 
HER4). Ligand binding causes receptor dimerization, activation 
of the kinase domains, auto-phosphorylation, and initiation of 
down-stream signaling. This generic scheme has two exceptions: 
HER3 contains no kinase domain and HER2 has no known 
ligand. Thus, HER2 and HER3 rely on hetero-dimerization with 
other ERBB receptors to initiate their cellular effects. The key 
pathways downstream of HER2 include PI3K and MAPK signal-
ing (Figure 1B) (7, 8). MAPK cascade includes sequential activa-
tion of RAS-RAF-MEK-ERK, which may stimulate proliferation 
through increased synthesis of CCND1 mediated by MYC and 
JUN/FOS transcription factors (9). The PI3K pathway starts 
with phosphorylation of PIP2 to PIP3, followed by activation 
of AKT. The de-phosphorylation of PIP3 to PIP2 is catalyzed by 
PTEN. The effect of PI3K-AKT signaling on proliferation may 
be mediated by inactivation of the p27 cell cycle inhibitor (10). 
Upon phosphorylation by AKT, p27 moves from the nucleus 
to the cytoplasm, thus allowing activation of CCNE1-CDK2 by 
CCND1-CDK4/6 and promoting G1-to-S cell cycle transition. 
Along with the effects on cell proliferation, PI3K-AKT signaling 
stimulates protein biosynthesis and inhibits apoptosis (11). Taken 
together, such downstream signaling explains the oncogenic 
effect of HER2 amplification in breast cancer.
DRUGS USeD FOR TReATMeNT OF 
HeR2-POSiTive MeTASTATiC BReAST 
CANCeR
Current medical treatment of HER2-positive metastatic breast 
cancer (MBC) combines HER2-targeted agents with cytotoxic 
and hormonal therapies.
HeR2-Targeted Agents
The HER2-targeted agents currently approved for treatment 
of MBC, include trastuzumab, pertuzumab, lapatinib, and 
trastuzumab-emtansine.
Trastuzumab
Trastuzumab (Herceptin) is a humanized monoclonal anti-
body binding to the extracellular portion of HER2 close to 
its transmembrane domain (Figure  1A) (12). It was the first 
HER2-targeted agent introduced to breast cancer clinics (2) 
and it remains a key component of the most effective regimens 
used to treat HER2-positive breast cancers now (13–15). Being 
an anti-HER2 antibody, trastuzumab has two main mechanisms 
of action: (i) it suppresses HER2 signaling and (ii) it triggers 
an antibody-mediated immune response. Studies on cell lines 
allowed exploration of the effect on the signaling without inter-
ference with immune-mediated mechanisms. It was shown that 
trastuzumab may inhibit HER2 signaling either by destabiliz-
ing HER2 heterodimers (12) or by causing internalization of 
HER2 receptors with subsequent lysosomal degradation (16). 
In addition, trastuzumab inhibits HER2 signaling by prevent-
ing cleavage of HER2 extracellular domain (17): the cleavage of 
HER2 ectodomain would create a functionally active truncated 
isoform of HER2 (p95-HER2) (18), which contributes to the 
tumors progression (19). It was also suggested that trastuzumab 
may inhibit HER2–cSRC interaction, resulting in the activation 
of PTEN that attenuates PI3K-AKT signaling (20). Importantly, 
trastuzumab has no clinical effect on HER2-negative tumors 
(21). Therefore, all its clinically relevant effects are mediated 
through HER2.
The contribution of immune mechanisms to the trastuzumab 
response was confirmed by preclinical and clinical studies of 
Fc-gamma receptors, involved in the cell-mediated immune 
response. Thus, trastuzumab effect on HER2-positive xenografts 
depends on function of Fc-gamma receptors (22), and genetic 
polymorphisms of Fc-gamma receptors are associated with clini-
cal response to trastuzumab (23). At the same time, it was noted 
that the contribution of immune mechanisms may be compro-
mised by immunosuppression when trastuzumab is combined 
with cytotoxic agents (24).
Patent protection of Genentech’s trastuzumab (branded as 
Herceptin) expired in 2014 in Europe and it will expire in 2019 
in the US. In 2013, a generic drug MYL-1401O with a protein 
sequence identical to Herceptin was manufactured by Mylan. 
After a phase III trial, which confirmed its clinical equivalency 
to Herceptin (25) in 2017, MYL-1401O (branded as Ogivri, 
trastuzumab-dkst) was approved by FDA as a biosimilar to 
Herceptin in the US. A number of other trastuzumab biosimilars 
have been approved in other countries.
Finally, a recent series of clinical trials demonstrated that 
trastuzumab can be administered subcutaneously, instead of con-
ventional intravenous administration. This makes trastuzumab 
treatment more convenient for patients and reduces associated 
health care costs (26), especially in metastatic settings, where 
trastuzumab is administered to fragile patients and treatment 
may last for several years.
FiGURe 1 | Human epidermal growth factor receptor 2 (HER2) signaling. (A) HER2 hetero-dimerization and HER2 targeting. (B) Signaling downstream of HER2 and 
its targeting.
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Pertuzumab
Pertuzumab is another monoclonal anti-HER2 antibody. It binds 
HER2 at a different location than trastuzumab (Figure  1A), 
primarily preventing formation of HER2-HER3 heterodimers 
(27). Pertuzumab was initially found to be effective in combina-
tion with trastuzumab (so-called “horizontal dual-blockade”) 
(28–30). Later, in a smaller study, pertuzumab was tested as a 
monotherapy; however, it showed much less efficiency than the 
combination (31). HER2-HER3 heterodimer is the most potent 
HER2 heterodimer, and combination of trastuzumab with 
pertuzumab is currently the most potent combination of HER2-
targeted agents [as shown in CLEOPATRA trial (32) discussed in 
more details later].
Lapatinib
Lapatinib is a small-molecule tyrosine-kinase inhibitor (TKI) 
targeting intracellular domains of HER2 and EGFR (Figure 1A). 
While it showed clinical activity in HER2-positive MBC (33, 
34), it is more toxic and less active than trastuzumab (35). Thus, 
lapatinib is reserved for use as an addition to trastuzumab (so-
called “vertical dual-blockade”) (30) in later lines of treatment 
in patients who cannot tolerate cytotoxic chemotherapy (36, 37) 
or with brain metastases (as discussed in more details in Section 
“Targeted Treatment of Brain Metastases”) (36, 38).
Trastuzumab-Emtansine, T-DM1
Trastuzumab-emtansine (also known as T-DM1 or Kadcyla) 
is an antibody-drug conjugate (ADC). This new class of drugs 
allows for targeted delivery of cytotoxic molecules to the tumor, 
potentially increasing their efficiency and reducing their toxicity 
at the same time (39). T-DM1 consists of a highly potent mitotic 
poison maytansine (DM1) linked to trastuzumab (40). Upon 
binding with HER2 on tumor cells surface the drug is internal-
ized, maytansine is released from the complex and inhibits micro-
tubule polymerization. Tested in clinic in the 1970s, maytansine 
displayed an unacceptably high toxicity without the targeted 
delivery (41). However, trastuzumab-delivered maytansine 
(T-DM1) showed a good safety profile, causing fewer serious 
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adverse effects (grade 3 or worse) than most of other treatment 
regimens in HER2-positive breast cancer (42–45). A series of 
phase-III trials showed high clinical efficacy T-DM1 in HER2-
positive MBC (MARIANNE, EMILIA, and TH3RESA—see 
Figure 2 and Section “Key Trials With Trastuzumab-Emtansine: 
TH3RESA, EMILIA, and MARIANNE”). T-DM1 is superior 
to other current HER2-targeting therapies in the second and 
later lines in patients pre-treated with trastuzumab or lapatinib 
(45, 46). In first line treatment, T-DM1 is non-inferior to the 
combination of trastuzumab and taxane, while showing better 
tolerability (42). T-DM1 is also being tested in combination with 
pertuzumab and taxanes (47).
Cytotoxic Component
Trastuzumab shows some activity as a monotherapy in HER2-
positive MBC (48). However, early addition of cytotoxic chemo-
therapy to trastuzumab markedly improves both the response 
rates and the overall survival of MBC patients (see Initial 
Trastuzumab Trials and Figure 2: Inoue 2010 and HERTAX trials) 
(49, 50). These clinical data are in agreement with the preclinical 
models, which showed synergistic and additive interactions of 
trastuzumab with chemotherapeutic agents used in BC (includ-
ing platinum agents, taxanes, and anthracyclines) (51). It was 
suggested that the synergy of trastuzumab with DNA-damaging 
chemotherapy, such as cross-linking platinum agents, may be 
explained by the inhibition of HER2-stimulated DNA-repair 
genes (52). Mechanism of the synergy with taxanes is less clear. 
However, it was hypothesized (53) that this may be mediated by 
inhibition of survivin expression (54, 55), which is involved in 
microtubule stabilization during mitosis (56).
A single cytotoxic agent is typically added to HER2-targeted 
treatment. Use of anthracyclines in HER2-positive MBC is 
limited because many patients were exposed to anthracyclines 
in the adjuvant setting, and because of the cumulative car-
diotoxicity of anthracyclines. Importantly, the anthracyclines 
cardiotoxicity overlaps with the toxicity of trastuzumab leading 
to high rates of heart failure in this combination (57). The 
cardiotoxicity is substantially reduced if HER2-targeted agents 
are combined with taxanes instead of anthracyclines. This made 
taxanes the treatment of choice for the cytotoxic component in 
the 1st line treatment of HER2-positive MBC (e.g., see the first 
line trials on Figure 2) (58). The most common taxane regimens 
include weekly paclitaxel or docetaxel administered at 3 weeks 
intervals. Nab-paclitaxel may be considered for patients that 
do not tolerate other taxanes or steroid premedication (e.g., 
for diabetic patients). Vinorelbine is considered as an alter-
native to taxanes, since it showed similar efficacy and better 
tolerability in 1st line HERNATA and VELVET trials (59, 60). 
Attempts of adding a second cytotoxic agent, e.g., combining 
trastuzumab + taxanes with capecitabine (CHAT trial) or with 
a platinum salt (BCIRG 007 trial) improved response rates at 
the expense of higher toxicity. Importantly, the addition of a 
second cytotoxic agent has provided no survival benefit in these 
trials (61, 62).
There is no strong evidence to select a cytotoxic agent after 
taxanes. Capecitabine is a convenient oral therapy. Its combina-
tion with HER2 targeted agents showed satisfactory clinical 
efficiency (63–65) and it is frequently used in second line clinical 
trials (Figure 2). The third line cytotoxic component may include 
vinorelbine, if not used earlier. At later lines, the most common 
physician choices include gemcitabine and eribulin (45), allowing 
the change of cytotoxic agents along several lines of metastatic 
treatment.
Hormonal Component
At least 50% of HER2-positive tumors express hormonal recep-
tors (66). This group of “triple-positive” breast cancers (TPBC) 
has distinct biology and clinical features (67, 68). Current 
approaches to treatment of metastatic TPBC will be discussed 
in more details in Section “Treatment of Triple-Positive Breast 
Cancer.” However, combining HER2-targeted and cytotoxic 
agents with endocrine therapies is one of the obvious options for 
this group of patients (14, 69). It has previously been shown that 
the addition of HER2-targeting to endocrine treatment improves 
outcomes in metastatic TPBC (see TAnDEM and EGF30008 trials 
on Figure 3) (70, 71). At the same time, there is much less clinical 
evidence about the opposite comparison: addition of endocrine 
therapy to HER2-targeted agents in MBC, although some EBC 
studies suggest that this may also be beneficial (72).
Until recently, the most common endocrine agents used in BC 
clinics were tamoxifen (for pre-menopausal patients) and aro-
matase inhibitors (AIs: letrozole, anastrozole, and exemestane) 
for post-menopausal patients. AIs could also be considered for 
patients of reproductive age after ovarian ablation (e.g., with gos-
erelin or oophorectomy). However, the preferences in selection of 
hormonal agents are likely to change in the view of several recent 
clinical trials. First, the FALCON study reported that adequately 
dosed fulvestrant is more effective than an AI for the first line 
ER-positive MBC (73). Subsequently, a series of trials showed 
that the addition of CDK4/6-inhibitors to endocrine treat-
ment significantly improves PFS in metastatic setting (74–76). 
None of these trials have included HER2-positive patients. 
However, a number of studies combining HER2-targeting with 
fulvestrant, AIs, or CDK4/6 inhibitors are already ongoing 
(PATINA, PATRICIA, and monarcHER trials: NCT02947685, 
NCT02448420, NCT02675231).
KeY TRiALS SUPPORTiNG CURReNT 
CLiNiCAL PRACTiCe
The results of key trials supporting current clinical practice in 
HER2-positive MBC are summarized in Figure 2.
initial Trastuzumab Trials
The pivotal trial by D. Slamon (2) showed for the first time a 
significant improvement of both PFS and OS after addition of 
trastuzumab to cytotoxic chemotherapy in HER2-positive MBC. 
The cytotoxic component in this trial included anthracyclines or 
taxanes. In addition to the proof of trastuzumab efficacy, the trial 
also highlighted the overlapping cardiotoxicity of trastuzumab 
and anthracyclines (57), paving the way for the wide use of 
taxanes in combination with trastuzumab in metastatic settings. 
This also established the practice of monitoring cardiac function 
during trastuzumab treatment.
FiGURe 2 | Selected trials supporting current practices in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). 
Abbreviations: T, trastuzumab; P, pertuzumab; L, lapatinib; Tx, taxanes; Cp, capecitabine; Ac, anthracyclines; Ph Ch, physician choice.  
(a) Difference between arms is not significant. (b) In the sequential arm Tx is added after progression on T alone. Median progression-free survival (PFS) is shown for 
T alone phase only. (c) Median overall survival (OS) is in favor of T + Tx, median OS not reached. (d) OS not reported. (e) After 3 T-containing lines on average.  
(f) After at least 2 metastatic lines. Median PFS and OS are indicated in months.
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FiGURe 3 | Triple positive breast cancer trials. Abbreviations: T, trastuzumab; P, pertuzumab; L, lapatinib; AI, aromatase inhibitor. (a) Mixed first line and later lines; 
median progression-free survival (PFS) and median overall survival (OS) for patients with centrally confirmed estrogen receptor. (b) OS trend not significant.  
(c) OS not reported. Median PFS and OS are indicated in months.
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Effectiveness of trastuzumab as a monotherapy was dem-
onstrated in a trial conducted by C. Vogel with co-authors 
(48). However, the reported PFS was noticeably inferior to the 
combined regimens reported earlier by D. Slamon. The direct 
comparison of trastuzumab mono-therapy and trastuzumab-
taxane combination could be derived from the two trials reported 
by K. Inoue and P. Hamberg (HERTAX trial) (49, 50). These trials 
have a very similar design and report similar findings. For ethi-
cal reasons, it was not possible to randomly withdraw cytotoxic 
treatment from MBC patients. So, the comparison was designed 
as a randomization between simultaneous and sequential admin-
istration of cytotoxics. In the simultaneous arms, the taxanes were 
added to trastuzumab starting from the beginning of the treat-
ment. In the sequential arms, the taxanes were added only after 
progression on trastuzumab alone. In both trials, the PFS in the 
trastuzumab-alone phase was markedly shorter than PFS in the 
trastuzumab-taxane combination. Moreover, the delay in add-
ing cytotoxic treatment significantly reduced OS in both trials. 
These trials convincingly show that trastuzumab monotherapy 
may only be reserved for the patients who are not suitable for 
combined regimens.
Dual-Block by Trastuzumab with 
Pertuzumab: CLeOPATRA
Further progress in treatment of HER2-positive MBC was linked 
to the development of “horizontal dual-blockade.” A phase III 
CLEOPATRA trial randomized 808 patients to either the standard 
trastuzumab-taxane arm or the new pertuzumab-trastuzumab-
taxane combination. The addition of pertuzumab led to statisti-
cally and clinically significant improvements in both PFS and OS. 
In particular, the median overall survival was extended by more 
than a year and reached in excess of 4.5 years (32). These results 
are as yet unsurpassed in HER2-positive MBC (if patients are 
not selected by hormonal receptor level); thus, the CLEOPATRA 
regimen has substituted trastuzumab-taxane combination as the 
treatment of choice in first line metastatic treatment. At the same 
time, it is worth noting that only ~10% of CLEOPATRA patients 
were previously exposed to trastuzumab (13, 77) and a recent 
PHEREXA trial reported much smaller benefit from addition of 
pertuzumab to trastuzumab-exposed MBC patients in second 
line treatment (78).
Key Trials with Trastuzumab-emtansine: 
TH3ReSA, eMiLiA, and MARiANNe
Effectiveness of trastuzumab-emtansine (T-DM1) has been 
shown in a series of phase III trials, which spanned line1 
(MARIANNE), line 2 (EMILIA), and later lines (TH3RESA). 
EMILIA and TH3RESA demonstrated superiority of T-DM1 
over lapatinib  +  capecitabine and over physician choice in 
trastuzumab-exposed patients (43–46). This shifted the lapat-
inib + capecitabine combination to third line, while T-DM1 has 
been accepted as the second line treatment of choice.
The first line MARIANNE study compared T-DM1 (±pertu-
zumab) with trastuzumab-taxane combination (which was the 
first line treatment of choice at the time of the study design). 
T-DM1 was non-inferior to trastuzumab-taxane and showed a 
better safety profile (42). No trial yet makes a direct comparison 
between T-DM1 and CLEOPATRA protocols. It could be noted 
that MARIANNE enrolled more patients exposed to trastu-
zumab than CLEOPATRA (~30 and ~10%, respectively) (13, 
77). However, in view of the clear superiority of CLEOPATRA 
protocol over trastuzumab-taxane, T-DM1 remains reserved for 
second line treatment (although there is no data about T-DM1 
efficiency in pertuzumab-exposed patients).
TABLe 1 | Current consensus sequencing of metastatic treatment in human 
epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer 
(MBC).
First line •	 Trastuzumab + Pertuzumab + Taxanes (vinorelbine may be 
considered instead of taxanes)
•	 Trastuzumab-emtansine (T-DM1) may be considered if patient 
is not suitable for the above or in case of a fast progression on/
after adjuvant Trastuzumab
Second line •	 Trastuzumab-emtansine (T-DM1)
•	 Trastuzumab + pertuzumab + cytotoxic chemotherapy (taxanes, 
vinorelbine, or capecitabine) may be considered if not exposed 
to pertuzumab previously
Third line •	 Regimens currently recommended for first or second line should 
be considered for the later lines, if not used previously
•	 Trastuzumab or lapatinib + cytotoxic chemotherapy (including 
vinorelbine, capecitabine, gemcitabine, eribulin, and others, if 
not used previously)
•	 Trastuzumab + lapatinib if not suitable for cytotoxic 
chemotherapy
Addition of endocrine therapy to HER2-targeted agents should be considered at any 
line after completion of cytotoxic chemotherapy in ER-positive patients.
Based on ASCO 2014 (69), NCCN 2017 (14), ESMO-ABC3 2017 (13, 77), AGO 2015 
(85), and SEOM 2015-2017 (15, 83, 84) guidelines.
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Selected Lapatinib Trials
Different lapatinib-containing combinations were tested in 
different metastatic settings. Adding lapatinib to chemotherapy 
significantly improves PFS and OS in first and second lines of 
treatment if compared to placebo (Guan-2013 and EGF00151 
studies, respectively) (33, 34, 79). However, a comparison with 
trastuzumab showed that lapatinib-taxanes combination has 
lower efficacy and higher toxicity than combination of taxanes 
with trastuzumab (MA-31 study) (35). Similarly, despite the 
proven activity of the lapatinib-capecitabine protocol in the 
second line (EGF00151 study) (34, 79), this combination was 
inferior to T-DM1 in EMILIA trial (43, 46). Thus, currently lapa-
tinib is reserved for third and later lines of treatment. Utility of 
lapatinib for patients with brain metastases will be discussed later 
in Section “Targeted Treatment of Brain Metastases.” Importantly, 
lapatinib is more effective in combination with trastuzumab (the 
“vertical dual blockade”) than taken alone, even in trastuzumab-
exposed patients (see EGF104900 and ALTERNATIVE trials on 
Figures  2 and 3) (36, 37, 80). This is in agreement with other 
studies confirming efficacy of trastuzumab beyond progression 
(63, 81).
CURReNT CONSeNSUS GUiDeLiNeS
Initial HER2-targeting clinical practices were shaped by tri-
als that demonstrated effectiveness of adding trastuzumab or 
lapatinib to chemotherapy in HER2-positive MBC (2, 33). It was 
also established that HER2-targeting should continue beyond 
progression through multiple lines of treatment (63, 81). Thus, 
the general consensus at the time was that trastuzumab + taxa-
nes could be considered as the first line treatment of choice 
(58, 82), followed by lapatinib- and capecitabine-containing 
combinations in second line (34). Overall, this practice was 
adopted from the time of the pivotal trial of D. Slamon in 2001 
(2) until the recent development of the horizontal dual-blockade 
(trastuzumab + pertuzumab) and T-DM1. The first results of a 
large T-DM1 trial in HER2-positive MBC (EMILIA PFS results) 
were published in 2012 (43). Similarly, the results of TH3RESA, 
MARIANNE, and CLEOPATRA were published between 2014 
and 2017 (32, 42, 44, 45). These trials called for a reassessment 
of previous clinical practices and led to updates in a number 
of guidelines released by expert panels around the world. The 
new consensus was set by the ASCO guidelines of 2014 (69), 
which was broadly followed by a number of other expert panels, 
including NCCN, ESMO, AGO and SEOM, to mention just a few 
within the past 3 years (13–15, 77, 83–85). The most commonly 
supported sequencing is summarized in Table 1. The guidelines 
agree that (i) dual-blockade with trastuzumab + pertuzumab is 
the preferred regimen for first line treatment; (ii) T-DM1 is the 
second line treatment of choice, and (iii) addition of lapatinib 
may be considered in the later lines. Pertuzumab-containing 
regimens and T-DM1 should also be considered in later lines 
for the patients, who have not received them earlier. Along with 
the current consensus, the guidelines highlight that the fast and 
simultaneous development of new HER2-targeted agents lead to a 
shortage of evidence regarding the use of these agents. Thus, more 
data is needed about the efficacy of trastuzumab-pertuzumab 
dual-block in trastuzumab-exposed patients. There is no data 
yet about efficacy of T-DM1 on pertuzumab-exposed patients or 
about the performance of lapatinib- and capecitabine-containing 
regimens on patients pre-treated with T-DM1.
ReMAiNiNG QUeSTiONS
In addition to the shortage of data about novel pertuzumab 
and TDM1-containing regimens, there is a list of other ques-
tions, which need to be further studied to improve treatment of 
HER2-positive MBC. These questions include (i) use of hormonal 
therapy in triple-positive breast cancers, (ii) treatment of brain 
metastases, (iii) assessment and conversion of HER2 expression 
in metastatic lesions, (vi) duration of treatment for metastatic 
patients with stable and complete response, (v) shortage of 
evidence about cancers resistant to adjuvant treatment, and (vi) 
treatment adjustments for elderly patients. The first two questions 
are of special importance in this list because they immediately 
affect treatment for a large proportion of HER2-positive MBC 
patients.
Treatment of Triple-Positive Breast Cancer
More than 50% of HER2-positive tumors also express estrogen 
receptors (66). These tumors are being increasingly recognized 
as a distinct group of breast cancers: “Triple Positive Breast 
Cancer” (TPBC) (68, 86, 87), whose unique biology is shaped by 
a complex interplay of HER2 and ER signaling (88–91). Optimal 
management of TPBC lies on the border between endocrine and 
HER2-targeted treatments. However, till recently, HER2-positive 
tumors have usually been excluded from endocrine trials, and 
studies of HER2-targeted agents often reported results without 
splitting them into ER-positive and ER-negative subgroups. 
So far, only a limited number of trials focused on metastatic 
TPBC patients (Figure 3). Three trials (TANDEM, EGF30008, 
and ELECTRA) showed that addition of HER2-targeting to 
TABLe 2 | Ongoing clinical trials in metastatic triple positive breast cancer 
(TPBC).
PATRICIA
NCT02448420
Phase II
Postmenopausal patients exposed to trastuzumab in 
previous metastatic setting
3 arms:
•	 Estrogen receptor (ER) negative, human epidermal 
growth factor receptor 2 (HER2) positive patients: 
palbociclib + trastuzumab
•	 ER positive, HER2 positive patients: 
palbociclib + trastuzumab
•	 ER positive, HER2 positive patients: 
palbociclib + trastuzumab + letrozole
Expected completion: 2019
monarcHER
NCT02675231
Phase II
TPBC after at least two HER2-targeted therapies for 
advanced disease
3 arms:
•	 Abemaciclib + Trastuzumab + Fulvestrant
•	 Abemaciclib + Trastuzumab
•	 Trastuzumab + Chemotherapy of physician choice
Expected completion: 2018–2019
PATINA
NCT02947685
Phase III
First line metastatic TPBC patients
2 arms:
•	 Palbociclib + Anti-HER2 therapy + Endocrine 
therapy
•	 Anti-HER2 therapy + Endocrine therapy
Induction cytotoxic chemotherapy is allowed prior 
randomization
Expected completion: 2020–2024
DETECT-V/CHEVENDO
NCT02344472
Phase III
TPBC patients with up to two prior therapies for the 
metastatic disease
2 arms:
•	 Trastuzumab + Pertuzumab + Cytotoxic 
chemotherapy
•	 Trastuzumab + Pertuzumab + Endocrine therapy
Quality of life and adverse effects as a primary 
outcome
Expected completion: 2021
SYSUCC-002
NCT01950182
Phase III
First line metastatic TPBC patients
2 arms:
•	 Trastuzumab + Cytotoxic chemotherapy
•	 Trastuzumab + Endocrine therapy
Expected completion: 2018
NCT03054363
Phase Ib–II
Tucatinib in combination with Palbociclib and 
Letrozole for first or second line metastatic TPBC.
In 2017, the study is not yet open for participant 
recruitment
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endocrine treatment significantly prolongs PFS, although 
the OS improvements in these trials did not reach statistical 
significance (70, 71, 92, 93). No randomized study has yet 
performed the opposite comparison: the addition of endocrine 
treatment to HER2-targeting agents. However, a retrospective 
analysis suggests that this may improve the results of treatment 
(72). Endocrine treatment has low toxicity, and multiple lines 
of evidence suggest that ER-positive tumors may have inferior 
response to cytotoxic treatment (94, 95). Taken together, these 
data justify addition of endocrine treatment whenever possible 
for ER-positive breast cancer, which led to the current ASCO 
and ESMO recommendations to add endocrine agents to the 
treatment for most TPBC patients in metastatic setting. Addition 
of the hormonal agents to HER2-targeted treatment is recom-
mended after completion of cytotoxic chemotherapy (13, 69, 77). 
Importantly, the guidelines emphasize that addition of endocrine 
therapy is not based on direct evidence. Also, they provide no 
reason why endocrine therapy should be delayed until comple-
tion of cytotoxic treatment.
The shortage of evidence about TPBC patients is being 
addressed by several recent and ongoing clinical trials summa-
rized in Figure 3 and Table 2. The recently reported PERTAIN 
trial was designed to evaluate the effect of horizontal dual-
blockade in metastatic TPBC (96). The control arm included 
trastuzumab + aromatase inhibitor, while the experimental arm 
added pertuzumab to the combination. Induction chemotherapy 
with taxanes prior the aromatase inhibitor was permitted at the 
discretion of the investigator (and was applied in ~50% cases in 
both arms). The analysis showed a significant increase in PFS 
after addition of pertuzumab. However, PERTAIN’s results may 
also be considered in a wider context. It was the first controlled 
trial that reported results of combining HER2-targeting, cyto-
toxic, and hormonal treatment at the same time—and the effect 
of such combination in both PERTAIN arms was unprecedented. 
Thus, median PFS in the experimental arm exceeded 2  years 
(27.1  months), which is an exceptional result for a metastatic 
cancer. Although PFS in the control PERTAIN’s arm was “just” 
15.1 month, it was comparable to PFSs reported in experimental 
arms by MARIANNE and CLEOPATRA (14.1 and 18.5 months) 
despite the fact that only half of PERTAIN patients received 
taxanes. Another interesting observation about PERTAIN was 
the very fact that investigators opted not to include taxanes in 
nearly 50% of cases, even though it was permitted by the protocol. 
The treatment sub-groups analysis (for patients with and without 
taxanes) and overall survival data of PERTAIN trial are awaited 
with interest.
The second recently reported metastatic TPBC trial is 
ALTERNATIVE (37). The study enrolled TPBC patients progress-
ing on a (neo)adjuvant/first line trastuzumab +  chemotherapy 
regimen. The treatment included three arms: trastuzumab vs. 
lapatinib vs. trastuzumab  +  lapatinib. Aromatase inhibitors 
were added in each arm. Patients intended for cytotoxic chemo-
therapy were excluded from this trial. The vertical dual blockade 
(trastuzumab  +  lapatinib combination) showed superior PFS 
as compared with lapatinib or trastuzumab alone (11, 8.3, and 
5.7 months, respectively). Again, despite the absence of cytotoxic 
treatment in this trial, the 11  months median PFS achieved in 
trastuzumab + lapatinib + AI arm was among the best reported 
in HER2-positive second line trials, such as EMILIA (9.6 months 
PFS for T-DM1) or PHEREXA (11.1 months for horizontal dual-
block + taxanes) (43, 78). It is not yet clear whether the exceptional 
PFS results reported by PERTAIN and ALTERNATIVE reflect the 
favorable intrinsic properties of TPBC or the good response to 
combined HER2- and ER-targeting; and these trials have not yet 
reported the overall survival data. However, these trials already 
provide interesting and encouraging data about new treatments 
and outcomes in metastatic TPBC.
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A significant progress has been made over the recent years 
in the treatment of metastatic ER-positive HER2-negative breast 
cancer: fulvestrant (500  mg) has been promoted to first line 
metastatic hormonal treatment (73) and CDK4/6 inhibitors have 
been established as a standard addition to endocrine agents (97). 
This progress triggered a series of trials testing whether these new 
approaches could be beneficial for TPBC patients (Table 2). Thus, 
phase II PATRICIA and monarcHER trials are studying addition 
of CDK4/6 inhibitors to trastuzumab (with or without hormonal 
treatment) in patients progressing after previous trastuzumab-
containing metastatic regimens. Phase III PATINA trial studies 
addition of CDK4/6 inhibitors to HER2-targeted agents in first 
line metastatic treatment (with or without hormonal therapy). 
Two other ongoing trials compare endocrine and cytotoxic thera-
pies in combination with HER2 targeting in metastatic TPBC 
(DETECT-V and SYSUCC-002 trials, see details in Table  2). 
All these trials are currently enrolling patients. The results are 
expected between 2018 and 2024.
Taken together, the recently reported and ongoing trials in 
metastatic TPBC will provide evidence to support new treatment 
standards for this group of patients. Finally, it could be noted that 
most metastatic TPBC patients were exposed to previous endo-
crine treatments in a (neo)adjuvant setting and/or in previous 
metastatic lines. Thus, testing for activating mutations in ligand-
binding domain of estrogen receptor may be helpful for rational 
selection of the endocrine component of their treatment (98).
Targeted Treatment of Brain Metastases
Brain metastases (BM) have a distinct biology and poor prognosis 
(99, 100). Currently, symptomatic BM is reported in 20–40% 
of HER2-positive MBC (101, 102). Additionally, up to 10% of 
patients may have asymptomatic BM detectable on autopsy (100). 
Incidence of BM is significantly higher in ER-negative than in 
ER-positive disease (99). Treatment of BM is based on radio-
therapy and surgery, supported by systemic therapies based on 
cytotoxic and targeted agents (103–105). The backbone systemic 
therapy could be combined with additional medication (such as 
corticosteroids and anti-epileptic drugs) that is beyond the scope 
of this review (106). Paradoxically, treatment with trastuzumab 
increases incidence of brain metastases (107–110), while prolong-
ing the time to BM (110) and overall survival of patients with BM 
(108, 111). This is commonly explained by trastuzumab’s success 
in suppressing extracranial metastatic sites, which allows time for 
brain metastases to develop and manifest clinically. Importantly, 
while achieving good extra-cranial control, trastuzumab has 
limited effect on brain metastases themselves because of its poor 
permeability through the blood–brain barrier (BBB). Thus, under 
conditions of unimpaired BBB, trastuzumab’s concentration in 
cerebrospinal fluid could be 420 times below its concentration 
in serum; even when BBB is compromised by irradiation, the 
concentration of trastuzumab in brain is still about 50 times 
lower than in blood (112). In contrast, small-molecule TKIs, like 
lapatinib, penetrate BBB much better (113). This raised expecta-
tions about a possible special role for TKIs in BM treatment and 
encouraged a number of small trials evaluating effect of lapatinib 
on BM in heavily pre-treated HER2-positive MBC patients (114). 
In these trials, lapatinib alone showed low CNS response rates 
(2–6%) and low PFS (up to 3 months). However, when lapatinib 
was combined with capecitabine, the objective response rates 
rose to 18–38% and PFS to ~5  months. For comparison, CNS 
PFS reported for cytotoxic chemotherapies alone did not exceed 
4 months at the time (114). Taken together, these trials suggested 
some CNS benefit from addition of lapatinib, although of a 
limited clinical significance in pre-treated population. In 2013, 
a small single-arm open-label trial tested lapatinib +  capecit-
abine combination on patients with previously untreated brain 
metastases (LANDSCAPE trial). It reported 66% CNS ORR and 
median PFS of 5.5 months (115). Excellent ORR in LANDSCAPE 
trial was reflected in some guidelines, including ASCO-2014 and 
EANO-2017 (104, 105). However, a later CEREBEL trial failed to 
show superiority of lapatinib + capecitabine over trastuzumab in 
preventing BM (38). Although interpretation of the CEREBEL 
trial is complicated by the unexpectedly low rates of BM (3–5%), 
this trial brought some caution toward the lapatinib + capecit-
abine regimen. More importantly, a sub-analysis of EMILIA 
trial directly showed that T-DM1 provides better OS than 
lapatinib +  capecitabine in patients with BM (116). Similarly, 
trastuzumab and/or pertuzumab trials showed improvement in 
overall survival for patients with BM (111, 117), despite the low 
penetrance of BBB for these drugs. This is commonly explained 
by the importance of extracranial control in patients with BM. 
Building on this evidence, the most recent ABC-3 guideline from 
ESO-ESMO does not recommend a change of systemic treat-
ment for patients with BM, providing stable extracranial disease 
(13, 77). A trastuzumab-containing regimen is still essential 
for patients with BM because of its contribution to extracranial 
control. However, considering the low penetrance of BBB for 
trastuzumab, patients with BM may be encouraged to participate 
in clinical trials (85, 105). Trials of new TKIs, such as neratinib, 
are underway (118). Future trials combining small molecules and 
antibody-based agents may also be expected, as well as the trials 
of new methods to increase BBB permeability (119).
THeRAPieS UNDeR DeveLOPMeNT
The HER2-targeted treatments developed over the past 20 years 
converted the unfavorable natural history of HER2-positive BC 
into favorable clinical outcomes. At the same time, the metastatic 
disease still remains incurable for most patients. The innate and 
acquired resistance to existing therapies requires development of 
novel agents and strategies. The range of new therapies that are 
currently under development for HER2-positive MBC include 
(i) new TKIs targeting ERBB receptors and inhibitors of their 
down-stream signaling, (ii) inhibitors of cell cycle, HSP90, and 
angiogenesis, (iii) HER2-targeted drug delivery, and (iv) new 
antibodies and immunotherapy aimed at HER2-positive BC.
New eRBB-Targeting TKis
Neratinib is classified as a pan-ERBB TKI because it binds and 
irreversibly inhibits all ERBB receptors except HER3 (118, 120). 
On the basis of ExteNET study, neratinib has been recently 
approved by the FDA for extended post-trastuzumab adjuvant 
treatment (121). However, neratinib yet failed to show superiority 
over comparators in metastatic settings. Comparison of neratininb 
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with trastuzumab (both in combination with taxanes) in first line 
treatment was performed by NEfERT trial, which reported iden-
tical PFS in both arms (12.9 months) and much higher toxicity 
in the neratinib arm (grade 3 diarrhoea developed in up to 30% 
of patients) (122). In a second line trial that compared neratinib 
monotherapy with the combination of lapatinib + capecitabine, 
the neratinib arm showed shorter PFS and OS than the combina-
tion (PFS 4.5 vs 6.8 and OS 19.7 vs 23.6  months, respectively, 
differences between arms are not significant) (123). At the same 
time, a sub-analysis of NEfERT-T trial showed that neratinib 
was more effective against brain metastases (relative risk of CNS 
recurrences 0.48, p = 0.002). Another pan-ERBB TKI, afatinib, 
was tested in several breast cancer trials, and has progressed to 
a phase III trial in the first line metastatic setting (LUX-Breast 
1). However, this trial was stopped after an interim assess-
ment showed that afatinib outcomes were less favorable than 
trastuzumab (124). Neither neratinib nor afatinib are currently 
approved for treatment of HER2-positive MBC outside of clinical 
trials (125), although new trials of neratinib may be expected in 
patients with brain metastases.
As an alternative to pan-ERBB inhibitors, a selective HER2-
specific TKI was developed by Array BioPharma (Tucatinib, 
formerly known as ONT-380 or ARRY-380). It was expected to 
reduce the off-target effects and high toxicity common for dual- 
and pan-ERBB inhibitors. In a phase I trial, Tucatinib showed 
promising efficacy and safety profile (126). It also showed capac-
ity to penetrate the BBB and some promising results in patients 
with brain metastases (127). In view of these phase I results, 
a phase II trial has been recently initiated, which combines 
tucatinib with trastuzumab and capecitabine in HER2-positive 
MBC (HER2CLIMB, NCT02614794). Another recently initialed 
tucatinib trial combines it with CDK4/6 and aromatase inhibitors 
in metastatic TPBC patients (NCT03054363). The results of these 
trials are awaited with interest.
Pi3K and mTOR inhibitors
PI3K and mTOR are key components in signaling downstream 
of HER2 (Figure  1B). The m-TOR inhibitor everolimus has 
been extensively studied in breast cancer, and it is approved 
for treatment of ER-positive HER2-negative BC on the basis 
of BOLERO-2 trial (128). However, it showed less encourag-
ing results in two large phase III trials in HER2-positive MBC 
(BOLERO-1 and BOLERO-3). BOLERO-1, which studied 
addition of everolimus to trastuzumab +  taxanes in first line 
metastatic treatment, reported that everolimus was associated 
with increased toxicity without any improvement in either PFS 
or OS (129, 130). BOLERO-3 tested addition of everolimus to 
trastuzumab +  vinorelbine in second line metastatic treatment 
for patients previously exposed to trastuzumab and taxanes. The 
addition of everolimus in the BOLERO-3 led to a statistically 
significant improvement of PFS (131). However, numerically 
the median PFS was prolonged by less than 2  months (7.0 vs 
5.8 months) and there was no improvement in OS (132). A joint 
analysis of BOLERO-1 and BOLERO-3 was conducted in search 
for biomarkers to select patients benefiting most from treatment 
with everolimus. It showed that somatic mutations in the PI3K 
pathway (PIK3CA, PTEN, and AKT1 genes) could be used to 
predict response, and that everolimus benefit was mainly limited 
to ER-negative patients (133).
Similarly, several PI3K inhibitors which have been previously 
studied in ER-positive HER2-negative BC, are currently at early 
stages of testing in HER2-positive disease (including buparlisib 
(134), alpelisib (135), taselisib-NCT02390427, and pictilisib-
NCT00960960). Like everolimus, none of these PI3K inhibitors 
is yet recommended for HER2-positive patients outside of 
clinical trials. However, they may be used in future personalized 
treatment of HER2-positive MBC if companion biomarkers are 
developed to select responsive patients.
CDK4/6 inhibitors
CDK4 and CDK6 are partners of Cyclin D1, the key cell cycle 
regulator controlling G1-S transition. Activated by Cyclin D1, 
CDKs 4/6 phosphorylate RB protein, which in turn releases 
E2F from RB-E2F complexes leading to activation of Cyclin E 
and downstream cell cycle machinery (Figure 1B) (136). Cyclin 
D1 is frequently amplified in human cancers, including breast 
cancer (137). Surprisingly, despite the central role of Cyclin D1 
in cell cycle regulation, mice lacking Cyclin D1 are viable and 
resistant to HER2(neu)-induced breast cancers (but not to breast 
cancers induced by MYC) (138). HER2-amlpified breast cancer 
cell lines are among the most sensitive to CDK4/6 inhibition 
(74). Along with the involvement in HER2-dependent carcino-
genesis, Cyclin D1 also plays a key role in signaling downstream 
of estrogen receptor (139). These molecular findings triggered 
interest in CDK4/6 inhibitors for breast cancer treatment, cul-
minating in several recently published large phase III clinical 
trials (PALOMA-2/3, MONALEESA-2, and MONARCH-2) that 
tested addition of different CDK4/6 inhibitors (palbociclib, ribo-
ciclib, and abemaciclib, respectively) to hormonal therapies in 
ER-positive HER2-negative MBC (75, 97, 140, 141). The success 
of these trials led to regulatory approvals and supported a wave 
of interest in CDK4/6 inhibitors for treatment of HER2-positive 
disease. Several ongoing CDK4/6 trials in HER2-positive MBC 
were discussed in the TPBC section of this review (PATRICIA, 
monarcHER, and PATINA, see Table  2). Notably, one of the 
PATRICIA arms also includes ER-negative patients. It was also 
reported that abemaciclib has good CNS penetration, showing 
similar concentrations in plasma and brain (142). Importantly, 
the effect of CDK4/6 inhibitors requires intact RB protein expres-
sion (143). Thus, RB loss (and other RB mutations) should be 
monitored before treatment with CDK4/6 inhibitors and after 
progression on treatment. At present, CDK4/6 inhibition is 
perceived as one of the most promising new directions in the 
treatment of HER2-positive MBC, which may soon be used in 
clinical practice (at least in TPBC patients) (144).
inhibitors of HSP90 and Angiogenesis
Experimental studies suggested a potential role for HSP90, angio-
genesis, and topoisomerase inhibitors in treatment of different 
types of cancer. However, clinical trials have not yet justified 
including these drugs into routine clinical practice in HER2-
positive MBC.
HSP90 is a chaperon protein, which is required for proper 
folding and function of hundreds of its client proteins (145), 
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including HER2 and its key downstream targets (146). Preclinical 
studies reported anti-tumor activity of HSP90 inhibitors on a wide 
range of BC cells, with HER2-positive cell lines being particularly 
sensitive (147). In 2011, a phase II clinical trial studied effect of 
an HSP90 inhibitor tanespimycin on 31 HER2-positive MBC 
patients who previously progressed on trastuzumab (148). It 
reported objective responses to the tanespimycin + trastuzumab 
combination in 22% of the patients with median PFS of 6 months 
and median OS of 17 months. While this was a positive result, 
the efficiency of tanespimycin + trastuzumab looked modest in 
comparison to trastuzumab-emtansine reported shortly after-
ward (EMILIA trial first reported in 2012: PFS 9.6 months and 
OS 30.9 months) (43). Another HSP90 inhibitor showed limited 
efficacy in HER2-positive MBC in a phase II trial reported in 
2013 (149). No further clinical trials of HSP90 inhibitors were 
reported in HER2-positive MBC since then. However, the overall 
interest and experimental studies of HSP90 are continuing, with 
focus on biological complexity of HSP90 functions in cancer 
(145, 150, 151).
Similarly, there were attempts to inhibit angiogenesis in 
HER2-positive metastatic cancer. Angiogenesis is highly 
specific for tumor tissue in adults (152). HER2 overexpression 
stimulates VEGF expression in breast cancer (153), potentially 
leading to poorer clinical outcomes (154). Phase I and II trials 
showed that inhibitors of angiogenesis (such as VEGF inhibitor 
bevacizumab) may have effect on some HER2-positive MBC 
(155). However, a phase III clinical trial of bevacizumab in 
HER2-positive MBC failed to detect an improvement in PFS in 
first line treatment (AVEREL trial) (156), which was consistent 
with an unsuccessful adjuvant trial in HER-positive EBC (BETH 
trial) (157). Since 2010, the FDA does not approve bevacizumab 
for any form of breast cancer. The current studies of angiogen-
esis inhibitors in breast tumors are focused on the search for a 
sub-set of tumors that may be responsive to this class of drugs 
(158, 159).
HeR2-Targeted Drug Delivery and 
immunotherapies
The success of T-DM1 stimulated development of other HER2-
targeted antibody-drug-conjugates (ADC). The main directions 
in development of new ADC include (i) new targeting antibodies, 
(ii) new conjugated drugs, and (iii) increasing the drug-to-
antibody ratio. Thus, DS-8201 is a conjugate of trastuzumab with 
a topoisomerase-1 inhibitor (160). Its development progressed 
to a phase I clinical trial, which confirmed safety and potential 
efficacy in T-DM1-exposed patients (161). Another novel ADC is 
XMT-1522. Its antibody part targets a new epitope on HER2, thus 
avoiding potential competition for epitopes with trastuzumab or 
pertuzumab if used in combination. Moreover, each XMT-1522 
antibody is conjugated with 15 molecules of a proprietary cytotoxic 
component auristatin. XMT-1522 showed significantly higher 
potency than T-DM1 in preclinical models (162). Currently, it is 
being tested in a phase I clinical trial (NCT02952729).
An alternative approach to HER-2 targeted drug delivery was 
tested by an antibody-conjugated liposomal doxorubicin formu-
lation called MM-302. It delivered drug to tumor in liposomes 
tagged with anti-HER2 antibodies. The intention was to expand 
doxorubicin therapeutic range by avoiding its cardiotoxicity. A 
recent phase II trial (HERMIONE) compared the combination of 
trastuzumab with MM-302 against a combination of trastuzumab 
with cytotoxic chemotherapy of physician choice in heavily pre-
treated HER2-positive MBC patients (163). MM-302 was well 
tolerated. However, the trial has been terminated after an interim 
review showed no efficacy benefit over the comparator. Another 
new strategy is non-antibody targeting. Thus, S. Pallerla with co-
authors designed a HER2-targeted doxorubicin-peptidomimetic 
conjugate (164). The targeting is achieved by a short peptide 
that selectively binds to HER2. The compound is still in an early 
preclinical phase. An interesting approach was reported by X. 
Kang with co-authors, who conjugated trastuzumab with gold 
nanoparticles, which allowed HER2-targeted photothermal 
tumor destruction (165). Potentially, this method avoids any 
chemotherapy-associated toxicity. However, the studies are also 
still at a preclinical phase (testing on xenografts).
Finally, it is well established that immune mechanisms may 
contribute to response to trastuzumab (see Trastuzumab Section) 
(22, 23). A new antibody, magretuximab (MGAH22), has been 
designed to enhance the antibody-dependent cell-mediated 
cytotoxicity against HER2-positive tumor cells. Its Fab region 
targets the same epitope as trastuzumab. However, its Fc region 
was modified to increase affinity to activating Fc-receptors on 
NK-cells and macrophages. Magretuximab was well tolerated and 
showed promising efficacy as a monotherapy in phase I clinical 
trial (166). A phase III trial, SOPHIA, is testing a combination 
of magretuximab  +  cytotoxic chemotherapy in trastuzumab-
exposed MBC patients (167). An alternative approach is used 
in ertumaxomab: an engineered multi-functional antibody that 
simultaneously binds HER2, CD3, and the Fc-gamma-receptors. 
Potentially, this might promote immune response by bringing 
the tumor cell, T-cell, and accessory immune cells together. So 
far, ertumaxomab has been tested in two phase I clinical trials 
that reported encouraging safety and efficacy (168, 169). Other 
immunotherapy approaches that already reached at least phase 
I–II trials, include immune checkpoints inhibitors (PANACEA 
and KATE2 trials: NCT02129556, NCT02924883), T-cell thera-
pies (170), and vaccines (171). Overall, despite still being at early 
stages of development, the new HER2-targeted drug delivery 
systems and immunotherapies show promise and may extend 
our armamentarium for treating HER2-positive MBC in future.
CONCLUSiON
High expression or amplification of HER2 defines a distinct group 
of breast cancers. 20 years ago it was considered as an intrinsically 
aggressive subtype associated with poor prognosis (1). However, 
the tumor dependence on HER2 has also provided a target for 
treatments, which dramatically changed the outcomes for this 
type of disease. Now, HER2-positive breast cancer is considered as 
a favorable subtype (3–6) with about 70% of EBC patients reach-
ing 10-year disease-free survival after the current HER2-targeted 
adjuvant treatments (172). While the metastatic HER2-positive 
BC remains incurable, HER2-targeting significantly prolonged 
the life of these patients too, with median overall survival 
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exceeding 4 years in recent clinical trials (32, 42). HER2-targeted 
agents currently approved for metastatic breast cancer, include 
trastuzumab, pertuzumab, trastuzumab-emtansine, and lapat-
inib. They are used in different combinations with each other and 
with other chemotherapeutic agents. The recent progress in treat-
ment of HER2-positive MBC was achieved by the development 
of horizontal dual blockade (pertuzumab +  trastuzumab) (32) 
and by HER2-targeted drug delivery (trastuzumab-emtansine) 
(42). The current studies focus on (i) accumulating new evidence 
about recently established treatment regimens, (ii) treatment 
stratification by expression of estrogen receptors, (iii) treatment 
of brain metastases, (iv) development of new tools for HER2-
targeting (new TKIs, antibodies, antibody-drug conjugates, and 
immunotherapies), and on (v) targeting pathways downstream of 
HER2 (including PI3K, mTOR and CDK4/6 inhibitors). Future 
therapies will be based on molecular profiling and companion 
diagnostics to allow monitoring and rational selection of targeted 
treatments for individual patients.
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